Exh. 10.7 Amendment No. 1 to Distribution and Supply Agreement This Amendment No. 1, dated as of July 15, 2004, by and between Omrix Biopharmaceuticals, Inc., a corporation organized under the laws of Delaware ("Omrix"), and Ethicon, Inc., a...Distribution and Supply Agreement • January 18th, 2006 • Omrix Biopharmaceuticals, Inc. • New York
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Distribution and Supply Agreement • September 14th, 2018 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • New York
This Distribution and Supply Agreement (the “Agreement”) is entered into as of June 28, 2011 (the “Effective Date”) by and between Cipher Pharmaceuticals Inc. (“Cipher”), an Ontario corporation located at 5650 Tomken Road Unit 16, Mississauga Ontario L4W 4P1, and Vertical Pharmaceuticals Inc. (“Distributor”), a corporation organized under the laws of the state of New Jersey with an address at 2400 Main Street, Suite 6, Sayreville, New Jersey 08872. Unless otherwise specified, all capitalized terms shall have the meaning specified in Article 1 herein.
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 3 to DISTRIBUTION AND SUPPLY...Distribution and Supply Agreement • September 14th, 2018 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • New York
This Amendment No. 3 (the “Third Amendment) to the Distribution and Supply Agreement (the “Agreement”) is entered into as of the 1st day of January, 2015 (the “Effective Date”) by and between Cipher Pharmaceuticals, Inc. (“Cipher”), an Ontario corporation located at 5650 Tomken Road, Unit 16, Mississauga Ontario 14W 4P1, Canada, and Vertical Pharmaceuticals, LLC, as successor to Vertical Pharmaceuticals, Inc. (“Distributor”), a Delaware limited liability company with an address at 2500 Main Street Extension, Suite 6, Sayreville, New Jersey 08872, each individually a “Party” and together the “Parties.”. Unless otherwise defined herein, all capitalized terms shall have the meaning specified in the Agreement.
Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential.] Exclusive Distribution and Supply AgreementDistribution and Supply Agreement • January 31st, 2023 • Sonoma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Exclusive Distribution and Supply Agreement is entered into as of January 26, 2023 (the “Effective Date”) by and between Sonoma Pharmaceuticals, Inc., a Delaware corporation having a place of business at 5445 Conestoga Court, Unit 150, Boulder, Colorado 80301 (“Supplier”) and Daewoong Pharmaceutical Co., Ltd., a having a place of business at 12, Bongeunsa-ro 114-gil Gangnam-gu, Seoul, Republic of Korea (“Distributor”).
DISTRIBUTION AND SUPPLY AGREEMENTDistribution and Supply Agreement • October 26th, 2023 • Capstone Dental Pubco, Inc. • Dental equipment & supplies • New York
This DISTRIBUTION AND SUPPLY AGREEMENT (“Agreement”) is made as of July 30 2013 (the “Effective Date”) by and between NIBEC Co. Ltd., a corporation organized and existing under the laws of Korea, with a principal place of business at Iwol electricity-electronic Agro-Industrial Complex, 1127, Sinwol-ri, Iwol-myeon, Jincheon-gun, Chungcheonguk-do, Korea (“NIBEC”) and the Keystone Dental, Inc., a corporation organized under the laws of the Commonwealth of Massachusetts, United States of America, with a principal place of business at 144 Middlesex Turnpike, Burlington, MA 01803 (“KEYSTONE DENTAL”), (each, individually, a “Party” and, collectively, the “Parties”).
1 EXHIBIT 10.21 * Certain confidential information contained in this document, marked by brackets, has been omitted and filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. THIRD AMENDMENT...Distribution and Supply Agreement • March 30th, 2001 • Corixa Corp • Biological products, (no disgnostic substances) • New Jersey
DISTRIBUTION AND SUPPLY AGREEMENT By and Between Molecular Pharmacology Limited (ACN 110 037 860) And: Molecular Pharmacology (USA) Limited DATED: OCTOBER 13, 2005Distribution and Supply Agreement • October 18th, 2005 • Molecular Pharmacology (USA) LTD • Gold and silver ores • Western Australia
Molecular Pharmacology Limited (ACN 110 037 860), a corporation duly organized and existing under the applicable laws of Australia, having an address at Level 1, 284 Oxford Street, Leederville, Western Australia ("MPL").
AMONGDistribution and Supply Agreement • September 28th, 2001 • Imclone Systems Inc/De • Biological products, (no disgnostic substances) • New York
EXCLUSIVE DEVELOPMENT, DISTRIBUTION, AND SUPPLY AGREEMENTDistribution, and Supply Agreement • October 29th, 2007 • Bioform Medical Inc • Pharmaceutical preparations • New York
This EXCLUSIVE DEVELOPMENT, DISTRIBUTION, AND SUPPLY AGREEMENT (the “Agreement”) is entered into as of October 27th, 2006 (the “Effective Date”), by and between (i) CryoLife, Inc., a Florida corporation, having a principal place of business at 1655 Roberts Blvd. NW, Kennesaw, Georgia 30144 (“Supplier”), and (ii) BioForm Medical, Inc., a Delaware corporation having a principal place of business at 1875 South Grant Street, Suite 110, San Mateo, California 94402 (“BioForm”).
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 2 to DISTRIBUTION AND SUPPLY...Distribution and Supply Agreement • September 14th, 2018 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • New York
This Amendment No. 2 to Distribution and Supply Agreement (this “Amendment”) is entered into as of November 21, 2013 (the “Effective Date”) by and between Cipher Pharmaceuticals Inc. (“Cipher”), an Ontario corporation located at 5650 Tomken Road Unit 16, Mississauga Ontario IAW 4Pl, and Vertical Pharmaceuticals, Inc. (“Distributor”), a corporation organized under the laws of the state of New Jersey with an address at 2500 Main Street Extension, Suite 6, Sayreville, New Jersey 08872. Unless otherwise defined herein, all capitalized terms shall have the meaning specified in the Agreement.
AMENDMENT NO. 1 to DISTRIBUTION AND SUPPLY AGREEMENT between CIPHER PHARMACEUTICALS INC. and VERTICAL PHARMACEUTICALS, INC.Distribution and Supply Agreement • September 14th, 2018 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • New York
This Amendment No. 1 to Distribution and Supply Agreement (this “Amendment”) is entered into as of March 27th, 2012 (the “Effective Date”) by and between Cipher Pharmaceuticals Inc. (“Cipher”), an Ontario corporation located at 5650 Tomken Road Unit 16, Mississauga Ontario L4W 41’1, and Vertical Pharmaceuticals, Inc. (“Distributor”), a corporation organized under the laws of the state of New Jersey with an address at 2400 Main Street, Suite 6, Sayreville, New jersey 08872. Unless otherwise defined herein, all capitalized terms shall have the meaning specified in the Agreement.
FIRST AMENDMENT TO AMENDED & RESTATED HDGT DISTRIBUTION AND SUPPLY AGREEMENTDistribution and Supply Agreement • February 13th, 2020 • Baker Hughes Co • Oil & gas field machinery & equipment
This First Amendment to the Amended & Restated HDGT Distribution and Supply Agreement (the “Amendment”), effective as of 16th of September 2019 (“Amendment Effective Date”), is made by and between General Electric Company, a New York corporation (“GE”), acting through its GE Power business (“GE Power”), and legal entities operating on GE Power’s behalf (collectively, “Supplier”), and Baker Hughes, a GE company, LLC, a Delaware limited liability company (“Distributor”) on behalf of itself and its Affiliates (each a “Party”, and collectively, the “Parties”).
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. DISTRIBUTION AND SUPPLY AGREEMENTDistribution and Supply Agreement • August 18th, 2020 • CytoDyn Inc. • Pharmaceutical preparations • Delaware
This Distribution and Supply Agreement (this “Agreement”) is entered into as of July 2, 2020, (the “Effective Date”) by and between American Regent, Inc., a New York corporation having an address at 5 Ramsey Road, Shirley, New York, 11967 (“American Regent”), and CytoDyn, Inc., a Delaware corporation having an address at 1111 Main Street, Suite 660, Vancouver, Washington 98660 (“CytoDyn”). American Regent and CytoDyn are each referred to herein individually as a “Party” and together as the “Parties”.
AMENDED AND RESTATED DISTRIBUTION AND SUPPLY AGREEMENTDistribution and Supply Agreement • March 4th, 2013 • Santarus Inc • Pharmaceutical preparations • New York
This Amended and Restated Distribution and Supply Agreement (this “Agreement”) is dated as of November 30, 2012 (the “Amended and Restated Effective Date”), by and among Santarus, Inc., a Delaware corporation (hereinafter referred to as “Manufacturer”), and Prasco, LLC, an Ohio limited liability company (hereinafter referred to as “Distributor”).
ANDDistribution and Supply Agreement • May 4th, 2004 • Dusa Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
RECITALSDistribution and Supply Agreement • May 16th, 2005 • Source Interlink Companies Inc • Services-direct mail advertising services • Illinois
Exclusive Distribution and Supply AgreementDistribution and Supply Agreement • August 15th, 2012 • Oculus Innovative Sciences, Inc. • Surgical & medical instruments & apparatus • New York
This Exclusive Distribution and Supply Agreement is entered into as of the latest date set forth on the signature lines below by and between, on the one part, Oculus Innovative Sciences, Inc., a Delaware corporation having a place of business at 1129 No. McDowell Boulevard, Petaluma, California, USA 94954 (hereinafter referred to as “Oculus”) and Oculus Technologies of Mexico, S.A. de C.V. (hereinafter referred to as “Manufacturer”), a limited liability corporation organized under the laws of Mexico, having a place of business at Industria Vidriera 81, Fracc. Industrial Zapopan Norte, 45130 Zapopan, Jalisco, Mexico, and, on the other part, More Pharma Corporation, S. de R.L. de C.V. (hereinafter referred to as “More Pharma”), a limited liability company organized under the laws of Mexico, having a place of business at Av. Ejército Nacional 926, Interior 203 Col. Los Morales, Sección Palmas 11540, Mexico City, Mexico.
License, Exclusive Distribution and Supply AgreementDistribution and Supply Agreement • August 15th, 2012 • Oculus Innovative Sciences, Inc. • Surgical & medical instruments & apparatus • New York
This License, Exclusive Distribution and Supply Agreement is entered into as of the latest date set forth on the signature lines below by and between, on the one part, Oculus Innovative Sciences, Inc., a Delaware corporation having a place of business at 1129 No. McDowell Boulevard, Petaluma, California, USA 94954 (hereinafter referred to as “Licensor”) and Oculus Technologies of Mexico S.A. de C.V. (hereinafter referred to as “Manufacturer”), a limited liability corporation organized under the laws of Mexico, having a place of business at Industria Vidriera 81, Fracc. Industrial Zapopan Norte, 45130 Zapopan, Jalisco, Mexico, and, on the other part, More Pharma Corporation, S. de R.L. de C.V. (hereinafter referred to as “Licensee”), a limited liability company organized under the laws of Mexico, having a place of business at Av. Ejército Nacional 926, Interior 203 Col. Los Morales, Sección Palmas 11540, Mexico City, Mexico.
FIRST AMENDMENT TO MARKETING, DISTRIBUTION AND SUPPLY AGREEMENTDistribution and Supply Agreement • March 16th, 2007 • Dusa Pharmaceuticals Inc • Pharmaceutical preparations
This FIRST AMENDMENT TO MARKETING, DISTRIBUTION AND SUPPLY AGREEMENT (the “First Amendment”) made as of the 10th day of January, 2007 (the “Effective Date”) among DUSA PHARMACEUTICALS, INC., a New Jersey corporation having a principal office and place of business at 25 Upton Drive, Wilmington, Massachusetts, USA 01887 (hereinafter called “DUSA”), and DAEWOONG PHARMACEUTICAL CO., LTD, a Korean corporation having a principal office and place of business at 163-3 Samsung-dong Gangnam-gu, Seoul, Korea, (hereinafter called “DAEWOONG”) and DNC DAEWOONG DERMA & PLASTIC SURGERY NETWORK COMPANY, a wholly-owned Korean subsidiary of DAEWOONG PHARMACEUTICAL CO., LTD having a principal office and place of business at 163-3 Samsung-dong Gangnam-gu, Seoul, Korea (hereinafter called “DNC” and collectively with DAEWOONG hereinafter called “D&D”).
AMENDMENT NO. 4 TO DISTRIBUTION AND SUPPLY AGREEMENTDistribution and Supply Agreement • August 9th, 2012 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
This Amendment No. 4 to Distribution and Supply Agreement (this “Amendment”) is made as of November 30, 2011, by and among ViroPharma Incorporated, a Delaware corporation (hereinafter referred to as “Manufacturer”), and Prasco, LLC, an Ohio limited liability company (hereinafter referred to as “Distributor”).
CAN-FITE BIOPHARMA LTD AND CIPHER PHARMACEUTICALS INC. DISTRIBUTION AND SUPPLY AGREEMENT DATED AS OF MARCH 20, 2015Distribution and Supply Agreement • March 27th, 2015 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations • New York
This Distribution and Supply Agreement (the “Agreement”) is entered into as of March 20, 2015, (the “Effective Date”) by and between Can-Fite BioPharma Ltd. (“Can-Fite”), an Israeli company located at 10 Bareket Street, Kiryat Matalon, PO Box 7537, Petah-Tikva, 49170, Israel, and Cipher Pharmaceuticals Inc. (“Distributor”), an Ontario corporation located at 5650 Tomken Road Unit 16, Mississauga Ontario L4W 4P1. Unless otherwise specified, all capitalized terms shall have the meaning specified in Article 1 herein.
AMENDMENT NO. 1 TO DISTRIBUTION AND SUPPLY AGREEMENTDistribution and Supply Agreement • August 9th, 2012 • Viropharma Inc • Pharmaceutical preparations • Delaware
This Amendment No. 1 to Distribution and Supply Agreement (this “Amendment”) is made as of June 10, 2008, by and among ViroPharma Incorporated, a Delaware corporation (hereinafter referred to as “Manufacturer”), and Prasco, LLC, an Ohio limited liability company (hereinafter referred to as “Distributor”).
Suneva Confidential AMENDED & RESTATED DISTRIBUTION AND SUPPLY AGREEMENT BETWEEN SUNEVA MEDICAL, INC. AND HANGZHOU ST. NOVA TRADE CO., LTD Suneva ConfidentialDistribution and Supply Agreement • July 13th, 2022 • Viveon Health Acquisition Corp. • Blank checks
THIS AMENDED & RESTATED DISTRIBUTION AND SUPPLY AGREEMENT (“Agreement”) is made as of this 6th day of June, 2017 (“Effective Date”) between
ContractDistribution and Supply Agreement • August 9th, 2012 • Viropharma Inc • Pharmaceutical preparations
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
DISTRIBUTION AND SUPPLY AGREEMENT by and between Auxilium Pharmaceuticals, Inc. and Prasco, LLC dated April 1, 2014Distribution and Supply Agreement • August 7th, 2014 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Distribution and Supply Agreement (this “Agreement”) is made as of April 1, 2014 (the “Effective Date”), by and between Auxilium Pharmaceuticals, Inc., a Delaware corporation (hereinafter referred to as “Manufacturer”), and Prasco, LLC, an Ohio limited liability company (hereinafter referred to as “Distributor”).
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. DISTRIBUTION AND SUPPLY AGREEMENTDistribution and Supply Agreement • November 7th, 2019 • Lannett Co Inc • Pharmaceutical preparations • Delaware
THIS DISTRIBUTION AND SUPPLY AGREEMENT (this “Agreement”) is made this 2nd day of August, 2019 (the “Effective Date”), by and between SINOTHERAPEUTICS INC., a limited company incorporated pursuant to the laws of the People’s Republic of China with a business address at 1F, Building 3, No. 99 Haike Road, Pudong, Shanghai and/or its Affiliates (“Supplier”), and LANNETT COMPANY, INC., a Delaware corporation having an address of 9000 State Road, Philadelphia, PA 19136 and/or its Affiliates (“Lannett”). Lannett and Supplier may be separately referred to as “Party” or jointly as “Parties.”
EXHIBIT 10.2 DISTRIBUTION AND SUPPLY AGREEMENT FOR BUSPIRONE TRANSDERMALDistribution and Supply Agreement • October 21st, 1996 • Sano Corp • Pharmaceutical preparations • New York
DISTRIBUTION AND SUPPLY AGREEMENT AMONGDistribution and Supply Agreement • August 11th, 2008 • New York
Confidential treatment requested by Bristol-Myers Squibb Company, Bristol-Myers Squibb Biologics Company and ImClone Systems Incorporated.
DISTRIBUTION AND SUPPLY AGREEMENTDistribution and Supply Agreement • June 20th, 2006 • Osiris Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Distribution and Supply Agreement by and between Osiris Therapeutics, Inc., a Delaware corporation having a principal place of business at 2001 Aliceanna Street, Baltimore, MD 21231 (“Osiris”), and Blackstone Medical, Inc., a Massachusetts corporation having a principal place of business at 90 Brookdale Dr., Springfield, MA 01104 (“Distributor”), is dated as of November 10, 2005 (the “Effective Date”). Osiris and Distributor may be referred to herein as a “Party” or, collectively, as the “Parties.”
DISTRIBUTION AND SUPPLY AGREEMENT BETWEEN PURDUE PHARMA L.P. AND KV PHARMACEUTICAL COMPANY DATED AS OF JUNE 9, 2009Distribution and Supply Agreement • June 10th, 2009 • Kv Pharmaceutical Co /De/ • Pharmaceutical preparations • New York
THIS DISTRIBUTION AND SUPPLY AGREEMENT is entered into as of June 9, 2009 between Purdue Pharma L.P., a Delaware limited partnership (“Purdue”), and KV Pharmaceutical Company, a Delaware corporation (“Distributor”).
License, Distribution and Supply Agreement to market Cholecalciferol in China, Hong Kong, Macau and TaiwanDistribution and Supply Agreement • September 8th, 2014
Hong Kong, 8 September 2014 - Lee’s Pharmaceutical Holdings Limited (“the Group” or “Lee’s”) (Main Board Stock Code: 0950; Website: www.leespharm.com) and Abiogen Pharma S.p.A. of Pisa, Italy today jointly announced the signing of an agreement for License, Distribution and Supply for marketing of Thorens® Cholecalciferol (or vitamin D3) throughout China, Hong Kong, Macau and Taiwan.
RECITALSDistribution and Supply Agreement • January 18th, 2006 • Omrix Biopharmaceuticals, Inc. • New York
AMENDMENT NO. 3 TO DISTRIBUTION AND SUPPLY AGREEMENTDistribution and Supply Agreement • August 9th, 2012 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
This Amendment No. 3 to Distribution and Supply Agreement (this “Amendment”) is made as of November 30, 2010, by and among ViroPharma Incorporated, a Delaware corporation (hereinafter referred to as “Manufacturer”), and Prasco, LLC, an Ohio limited liability company (hereinafter referred to as “Distributor”).
ContractDistribution and Supply Agreement • August 11th, 2008 • New York
[NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE THAT CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR SUCH PORTIONS BY BRISTOL-MYERS SQUIBB COMPANY, BRISTOL-MYERS SQUIBB BIOLOGICS COMPANY AND IMCLONE SYSTEMS INCORPORATED. THESE PORTIONS HAVE BEEN MARKED WITH TWO ASTERISKS ENCLOSED IN BRACKETS (i.e., [**]). THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]
DISTRIBUTION AND SUPPLY AGREEMENT BETWEEN KLOX TECHNOLOGIES INC. AND SANDOZ CANADA INC. NOVEMBER 15, 2013Distribution and Supply Agreement • January 12th, 2015 • Klox Technologies, Inc. • Pharmaceutical preparations • Quebec
This Distribution and Supply Agreement is entered into at the City of Montreal, Province of Quebec, on this 15th day of November, 2013 (the “Effective Date”) by and between:
